North very interesting and just trying to recap here, related to Dr Jedd Wolchok
We know the ties from Dr Wolchok to Juno after patient deaths....immediately after is when Peregrine was in with Dr Wolchok and maybe we can suspect that after patient deaths with another biotech...and bringing Dr Wolchok on board would also mean he would advise to reduce off Target toxicities / deaths, that PS Targeting is required.
What changes have Ziopharm made after patient deaths, especially with Dr Jedd Wolchok on board with Ziopharm and knowing PS Targeting reduces off Target toxicities ?
Other Affiliations Caladrius Biosciences, Inc. Princeton University New York University Altor BioScience Corporation American Society Of Clinical Oncology, Inc. NYU Elaine A. and Kenneth G. Langone Medical Center Cancer Research Institute, Inc. ZIOPHARM Oncology, Inc. Cytokines, Cellular and Molecular Therapy Syndax Pharmaceuticals, Inc. BeiGene, Ltd. SELLAS Life Sciences Group AG IFM Therapeutics, Inc.